Home Journals Subjects About My LA Reviewers Authors News Submit
Username: Password:
.
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


Enter the three character code
Visual CAPTCHA
Privacy Statement

Database Analysis of Adults with Bipolar Disorder Consuming a Micronutrient Formula

Authors: Dermot Gately and Bonnie J. Kaplan
Publication Date: 01 Apr 2009
Clinical Medicine: Psychiatry 2009:2 3-16

Dermot Gately1 and Bonnie J. Kaplan2

1Department of Economics, New York University, New York, NY, U.S.A. 2Departments of Pediatrics, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

Abstract

Background:  Bipolar disorder is a lifelong problem with imperfect available treatments. Recent research has shown potential benefit of nutritional treatment for mood symptoms. The goal of the current study was to determine whether adults with bipolar disorder reported treatment benefit from consuming a micronutrient formula.

Methods:  Self-report data were available from 682 adults who reported a diagnosis of bipolar disorder; 81% were taking psychiatric medications. Those reporting additional diagnoses were excluded, as well as those who provided data 60 times during 180 days of using the micronutrients, leaving 358 for analysis.

Results:  Mean symptom severity was 41% lower than baseline after 3 months (effect size = 0.78), and 45% lower after 6 months (effect size = 0.76) (both paired t-tests significant, p  0.001). In terms of responder status, 53% experienced 50% improvement at 6 months. Half the sample were taking medications approved for bipolar disorder (lithium, anticonvulsants, atypical antipsychotics), and half were either medication-free or taking other medications: the magnitude of treatment benefit did not differ between these two groups. Regression analyses indicated that decreased symptom severity over the 6 months was associated with increasing micronutrient dosage and with reducing medication. Symptom improvements were significant and sustained at 6 months, suggesting that benefits were not attributable to placebo/expectancy effects.

Conclusions:  Further research on this micronutrient formula is warranted.


REQUEST FROM THE AUTHORS

We are grateful to the people who have shared their personal experience with EMPowerplus, but we believe that the posted comments in this forum should address the scientific aspects of the paper.

People wishing to share their experiences with EMPowerplus are invited to do so through the product's developer, Truehope Nutritional Support Ltd., whose main website is Truehope.com.

Those who would like to post their stories can go to mytruehope.net and enter their username and password; then click on Message Boards.  If you do not have a username and password, you can contact Michelle at Truehope @ 1-888-878-3467 and she will arrange it for you.

Thank you, sincerely, for your interest in our research.
D. Gately and B. Kaplan